Company Description
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system.
Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD.
The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.
Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Gregory D. Gorgas M.B.A. |
Contact Details
Address: 505 Lomas Santa Fe, Suite 160 Solana Beach, California 92075 United States | |
| Phone | 858-925-7049 |
| Website | artelobio.com |
Stock Details
| Ticker Symbol | ARTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001621221 |
| CUSIP Number | 04301G201 |
| ISIN Number | US04301G5080 |
| Employer ID | 33-1220924 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory D. Gorgas M.B.A. | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Andrew Yates Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Steven D. Reich | Chief Medical Officer |
| Jason H. Baybutt | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 4, 2024 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Aug 10, 2023 | 10-Q | Quarterly Report |
| Aug 8, 2023 | 8-K | Current Report |
| Jul 14, 2023 | EFFECT | Notice of Effectiveness |
| Jul 7, 2023 | DEL AM | Filing |
| Jul 6, 2023 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 3, 2023 | 8-K | Current Report |